H+ channel inhibitors as anti-cancer drugs

Picture1-removebg-preview copy.png

Developing innovative therapeutics by targeting pathways based on 30+ years of research at the University of Geneva

Blue Gradient

ABOUT US

HPlus is developing innovative therapeutics by targeting pathways based on more than 30 years of research at the University of Geneva. The company’s sole focus is the study of the Hv1 proton channel.

1.4 million CHF of grant funding already raised. HPlus is now seeking 1 million CHF to continue HIT to LEAD phase and to secure IP protection. First disease indication: Granulocytic Sarcome

JHGJ 1.png
 

TEAM

 
7 1.png
Dr. Zhukovsky, Dr. Niquille,
Dr. Brun, Dr. Mosser
2.png
Dr. Chemaly
3.png
Mr. Cambet
4_edited.jpg
Prof. Demaurex
5.png
Dr. Jaquet
6.png
Prof. Krause

CONTACT US

Avenue de la Roseraie 64, 1205 Genève

n.zhukovsky@hplus-therapeutics.com 

Thanks for submitting!